Boman Eeva, Kapanen Mika, Pickup Lyndsey, Lahtela Sirpa-Liisa
Department of Oncology, Tampere University Hospital, PO BOX 2000, FI-33521 Tampere, Finland; Department of Medical Physics, Tampere University Hospital, PO BOX 2000, FI-33521 Tampere, Finland; Department of Radiation Oncology, Wellington Blood and Cancer Centre, Wellington Hospital, Wellington 6242, New Zealand.
Department of Oncology, Tampere University Hospital, PO BOX 2000, FI-33521 Tampere, Finland; Department of Medical Physics, Tampere University Hospital, PO BOX 2000, FI-33521 Tampere, Finland.
Med Dosim. 2017;42(4):296-303. doi: 10.1016/j.meddos.2017.06.006. Epub 2017 Jul 21.
The purpose of this study is to evaluate the effect of nonrigid and fractionation-corrected dose summation on total doses in radiotherapy and to demonstrate the benefits of such dose summation on clinical decision-making for planning of retreatments. Dose summation of organs at risk (OARs) was investigated for 3 clinical cases with need of retreatment to the same site: head and neck, brain, and mediastinum. Three different summation methods over old and new radiotherapy treatment plans are presented and compared: (1) rigid raw sum with rigid registration of the planning images and direct dose summing; (2) deformable raw sum with deformable image registration and direct dose summing; and (3) deformable biological sum with deformable registration and takes into account the dose per fraction in biological manner in certain critical organs. In 2 cases, a user-defined dose downscaling is applied to take into account the time between the treatments and the healing from the radiation-induced effects. Of the 3 summation methods presented, the deformable biological sum was considered to offer the most biologically plausible account of the treatment. There were remarkable differences between near-maximum doses (D0.1cc) and dose-volume histogram (DVH) curves for OARs between different summation methods. The differences between deformable raw sum and rigid raw sum D0.1cc doses are in the range from -8 Gy to 2 Gy. Similarly, the deviation was from -14 Gy to 5 Gy for the deformable biological sum compared with the rigid raw sum. These differences come from incorrect summation of doses in the rigid raw sum case, and from the dose per fraction effect in biological summation. We conclude that computing the 3-dimensional deformable biological summation could be a valuable tool for treating patients with complex retreatments. It has the potential to assist the oncologist in refining plans for maximally curative doses while respecting appropriate tissue tolerances.
本研究的目的是评估非刚性和分次剂量校正的剂量求和对放射治疗总剂量的影响,并证明这种剂量求和在再治疗计划的临床决策中的益处。对3例需要对同一部位进行再治疗的临床病例(头颈部、脑部和纵隔)的危及器官(OARs)进行了剂量求和研究。提出并比较了旧的和新的放射治疗计划的三种不同求和方法:(1)刚性原始求和,通过规划图像的刚性配准和直接剂量求和;(2)可变形原始求和,通过可变形图像配准和直接剂量求和;(3)可变形生物求和,通过可变形配准,并以生物学方式考虑某些关键器官的分次剂量。在2例病例中,应用了用户定义的剂量缩减,以考虑两次治疗之间的时间间隔以及辐射诱导效应的恢复情况。在所提出的3种求和方法中,可变形生物求和被认为提供了最符合生物学原理的治疗描述。不同求和方法之间,OARs的近最大剂量(D0.1cc)和剂量体积直方图(DVH)曲线存在显著差异。可变形原始求和与刚性原始求和的D0.1cc剂量之间的差异范围为-8 Gy至2 Gy。同样,与刚性原始求和相比,可变形生物求和的偏差为-14 Gy至5 Gy。这些差异源于刚性原始求和情况下剂量的不正确求和,以及生物求和中的分次剂量效应。我们得出结论,计算三维可变形生物求和可能是治疗复杂再治疗患者的一种有价值的工具。它有可能帮助肿瘤学家在尊重适当的组织耐受性的同时,优化最大根治剂量的计划。